Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SP-002,Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Stamford Pharmaceuticals Announces First Patient Treated with SP-002 in Phase 2 BCC Study
Details : SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : SP-002,Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2022
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2017
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 29, 2016
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 24, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vismodegib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable